Click here to take the CME Evaluation and Post-Meeting Survey
Craig Hendrix trained in infectious diseases and clinical pharmacology at Hopkins before 10 years as an Air Force physician and 23 years at Johns Hopkins. Dr. Hendrix’s primary research focus is clinical pharmacology of HIV pre-exposure prophylaxis and served as Principal Investigator of over 75 phase I clinical studies. He’s also served as principal pharmacologist for over 50 clinical trials in the Microbicide Trials Network and HIV Prevention Trials Network. He has published over 250 original scientific papers.
He has also served as member of a National Academy of Medicine Advisory Panel, the CDC Board of Scientific Counselors, the board of several pharmacology professional societies, current Chairman of the Board of the American Board of Clinical Pharmacology, and member of several FDA Advisory Committees. He has received numerous awards for scientific achievement.
At the completion of this educational session, learners will:
1. Describe the benefits of PrEP choices for global HIV prevention.
2. Understand the limitations of systemic, long-acting PrEP.
3. Discuss ongoing development of on-demand PrEP.
4. Discuss ongoing development of multi-purpose prevention technologies (MPTs).
This CME activity has approved for AMA PRA Category 1 Credit™
for April 14, 2021 as a live activity. This activity will also be available as an enduring activity from April 15, 2021, through April 13, 2024.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Craig W. Hendrix (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research Funding, SAB paid and travel from Merck, ViiV, and Population Control; Research Funding and SAB travel from Gilead; Travel from RTI; Founder/Officer of Prionde Biopharma. Dr. Hendrix will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.
This PRN CME activity is funded in part by unrestricted educational grants from:
Click here to take the CME Evaluation and Post-Meeting Evaluation
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare